2,3,4,5-tetrahydro-1H-benzo[b]azepin-8-amine | 518051-96-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 2,3,4,5-tetrahydro-1H-benzo[b]azepin-8-amine
• 英文别名: 2,3,4,5-tetrahydro-1H-1-benzazepin-8-amine
• CAS: 518051-96-2
• 化学式: C₁₀H₁₄N₂
• 分子量: 162.235
• InChiKey: KNIPUMXQKNWUSP-UHFFFAOYSA-N

物化性质

• 沸点：
  335.1±31.0 °C(Predicted)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3,4,5-tetrahydro-1H-benzo[b]azepin-8-amine 在 甲醇 、 碳酸氢钠 、 lithium tert-amoxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1,3-oxazolidin-5-yl]methyl]acetamide
  参考文献：
  名称：

  Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials

  摘要：

  Novel benzazepine oxazolidinone antibacterials were synthesized and evaluated against clinically relevant susceptible and resistant organisms. The effect of ring nitrogen position and N-substitution on antibacterial activity is examined. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.017
• 作为产物：
  描述：

  1,3,4,5-四氢-2H-1-苯并氮杂卓-2-酮 在 palladium on activated charcoal lithium aluminium tetrahydride 、 硫酸 、 硝酸 、 肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 2,3,4,5-tetrahydro-1H-benzo[b]azepin-8-amine
  参考文献：
  名称：

  Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials

  摘要：

  Novel benzazepine oxazolidinone antibacterials were synthesized and evaluated against clinically relevant susceptible and resistant organisms. The effect of ring nitrogen position and N-substitution on antibacterial activity is examined. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.07.017

文献信息

• Androgen receptor modulators and methods of use thereof
  申请人：——

  公开号：US20040198717A1

  公开（公告）日：2004-10-07

  Compounds of structural formula (I) are disclosed as useful for modulating the androgen receptor (AR) in a tissue selective manner in a patient in need of such modulation, and in particular for antagonizing AR in the prostate of a male patient or in the uterus of a female patient and agonizing AR in bone and/or muscle tissue. These compounds are useful in the treating conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including: osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, post-menopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, arthritis and joint repair, alone or in combination with other active agents. In addition, these compounds are useful as pharmaceutical composition ingredients alone and in combination with other active agents.

  结构式（I）的化合物被披露为对需要这种调节的患者中的雄激素受体（AR）进行组织选择性调节的有用物质，特别是在男性患者的前列腺或女性患者的子宫中对AR进行拮抗，以及在骨骼和/或肌肉组织中对AR进行激动作用。这些化合物在治疗由雄激素缺乏引起或可通过雄激素治疗改善的疾病中有用，包括：骨质疏松症，牙周病，骨折，骨重建手术后的骨损伤，肌无力，虚弱，老化皮肤，男性性腺功能减退，女性性功能障碍，女性更年期症状，动脉硬化，高胆固醇血症，高脂血症，再生障碍性贫血和其他造血障碍，胰腺癌，肾癌，前列腺癌，关节炎和关节修复，单独或与其他活性成分组合使用。此外，这些化合物作为药物组成部分，单独或与其他活性成分组合使用，也是有用的。
• ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF
  申请人：Merck & Co., Inc.

  公开号：EP1439841A2

  公开（公告）日：2004-07-28
• EP1439841A4
  申请人：——

  公开号：EP1439841A4

  公开（公告）日：2005-11-09
• FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS
  申请人：Cephalon, Inc.

  公开号：EP2222647A1

  公开（公告）日：2010-09-01
• US7196076B2
  申请人：——

  公开号：US7196076B2

  公开（公告）日：2007-03-27